Target customers frequently turn to pharmacists for allergy advice, survey finds
MINNEAPOLIS — More than half of allergy sufferers seek advice from pharmacists and doctors, a new survey by Target has found.
The survey found that of the 70% of American adults with spring allergies, 56% seek advice from a pharmacist or doctor. The 2,111-person survey was conducted online by Harris Interactive on behalf of the mass merchandise retailer. The survey also found that 34% of respondents said the worst parts of the spring allergy season were the side effects of medication, while 32% cited being unable to enjoy time outside and another 32% cited sleep interference, but only 25% said they were prepared for allergy season.
"As Americans begin to take more control over their healthcare choices, pharmacists have emerged as a valuable and trusted resource," Target associate medical director Kevin Ronneberg said. "Target pharmacists serve as a partner on both sides of the counter and can help guests find relief by identifying the best over-the-counter products to alleviate and treat specific allergy symptoms and triggers."
Surveying 1,200 of its own pharmacists on the top concerns expressed by customers with allergies, Target found that pharmacists frequently had to answer questions about drugs they would recommend to alleviate symptoms, the difference between private label and branded OTC medicines, and which medicines are safe for children.
Three-stage pacifier brand, popular in Europe, to be marketed in U.S.
NEW YORK — Difrax is selling its brand of three-stage pacifiers in the United States, the company said.
The company said it would start marketing the pacifiers after a successful run in Europe. The pacifiers, which are available in classic and orthodontic styles, have a three-stage design to accommodate babies’ growth and development, including a soft-nipple stage for newborns and babies ages 6 months; another stage with a larger and slightly firmer nipple for those ages 6 to 18 months; and a solid nipple for those ages 18 months and older that is described as less satisfying and designed to prepare children for weaning.
Both pacifier styles have a butterfly shape to prevent the nose from being obstructed and holes to allow airflow and reduce skin irritation. The three stages sell for $5.49, $5.99 and $5.99, respectively.
WAG’s latest moves offer brighter outlook on Wall Street
To the skepticism of many, Walgreens last year made a big global splash with its two-step merger deal with Alliance Boots across the pond. But with the announcement that the co-joined Walgreens/Alliance Boots had signed a 10-year distribution deal with wholesaler AmerisourceBergen, that included an equity stake to boot, well, it seemed that many analysts on Wall Street finally got it. With the ability to source and distribute generics globally and with the kind of buying clout generated by the joined forces of Walgreens, Alliance Boots and AmerisourceBergen, it’s a good bet these companies will reward shareholders with greater returns over the long haul.
Walgreens’ shares were up 12.3% to $47.66 per share in the three weeks following the March 19 announcement of the AmerisourceBergen deal; AmerisourceBergen’s shares were up 9% to $52.63 per share.
"While not a game changing deal in terms of earnings, the agreement reduces [Walgreens’] distribution costs, enhances the synergy potential of its purchasing [joint venture] with Alliance Boots [and] streamlines its supply chain," Credit Suisse analyst Ed Kelly, who remains "neutral" on Walgreens’ stock, reported in a research note following the deal. "This looks to be a good strategic move. … While we have not been fans of some of the decisions at Walgreens over the last couple years, … the outlook beyond the second half looks to be improving."
As the entire world wrestles with the common problems of paying for health care, Walgreens emerges as the biggest buyer of generic drugs in the world, positioned to be the lowest-cost provider with the biggest profits to show for it.
$13 billion — that’s the collective estimated generic drug purchasing power Walgreens now has, according to Lazard Capital Markets estimates. This compares to around $8 billion for McKesson, as much as $6 billion for CVS Care-mark and around $5 billion for Cardinal.
But purchasing power isn’t the only synergy. The real opportunity remains in expansion opportunities in those markets where generics are still underutilized, which is just about everywhere else in the world. And it’s not just an opportunity for Walgreens; it’s also an opportunity for Walgreens’ pharma partners, who are actively looking beyond the U.S. market for growth opportunities.
For example, the Walgreens/Alliance Boots combination can go a long way toward improving compliance and adherence on a global scale, if the companies can clear the operational hurdle of disparate healthcare markets. A 5% improvement in patient adherence could be worth as much to a drug maker in one year as a brand-new blockbuster drug launch, and without any of the research and development costs.
Buying clout, healthcare cost savings and improved adherence for pharma partners — those are the collective advantages Walgreens has been creating with its reach overseas. Finally, Wall Street is beginning to reward it for that.